<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889460</url>
  </required_header>
  <id_info>
    <org_study_id>VO58.07 DK</org_study_id>
    <nct_id>NCT00889460</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of rBet v1 SLIT Tablets</brief_title>
  <official_title>Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of several doses of r
      Bet v1 administered as sub-lingual tablets in subjects sensitised to birch pollen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>Assessed every day over 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global safety</measure>
    <time_frame>Assessed every day over 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological markers (IgE and IgG4)</measure>
    <time_frame>Between selection and follow-up visit (up to 18 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Birch Pollen-Related Rhinoconjunctivitis</condition>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rBet v 1 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rBet v 1</intervention_name>
    <description>Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>rBet v 1.0101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written consent

          -  Male or female subject from 18 to 60 years old and in general good health

          -  For woman of child bearing potential:

          -  Symptoms of birch pollen induced allergic rhinitis for at least the last 2 years.

          -  Sensitisation to birch pollen as demonstrated with a positive SPT to birch pollen and
             specific IgE level (birch pollen and r Bet v1) &gt;0.70 kU/L at screening.

          -  FEV1 at least of 80% of predicted values at screening.

          -  Subject accepting to comply fully with the protocol.

        Exclusion Criteria:

          -  Past or current disease which as judged by the Investigator, may affect the outcome of
             this study.

          -  History of life-threatening asthma,

          -  Asthma requiring daily treatment (whatever the pharmaceutical class).

          -  Pregnant or lactating woman.

          -  Subject being treated with inhaled steroids within 4 weeks prior to screening visit or
             within 12 weeks prior to screening visit.

          -  Subject who previously received desensitisation treatment to birch pollen and/or other
             betulaceae (e.g., hazel tree, alder) or who plan to start desensitisation treatment
             during this study.

          -  Symptoms during the treatment phase due to a sensitivity to a second allergen.

          -  Subjects treated with ongoing immunotherapy with another allergen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Jorgen MALLING, Pr. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital - Copenhagen - DENMARK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital - Allergy Unit 4222</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>L. Winther, L.K. Poulsen, B. Robin, M. Mélac, H. Malling Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT) The Journal of Allergy and Clinical Immunology February 2009 (Vol. 123, Issue 2, Page S215)</citation>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>April 28, 2009</last_update_submitted>
  <last_update_submitted_qc>April 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Bruno ROBIN</name_title>
    <organization>Stallergenes S.A.</organization>
  </responsible_party>
  <keyword>rBet v 1</keyword>
  <keyword>Birch pollen allergy</keyword>
  <keyword>Sublingual Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

